<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37026113</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2314-7156</ISSN><JournalIssue CitedMedium="Internet"><Volume>2023</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Journal of immunology research</Title><ISOAbbreviation>J Immunol Res</ISOAbbreviation></Journal><ArticleTitle>Potential Targets and Mechanisms of Jiedu Quyu Ziyin Decoction for Treating SLE-GIOP: Based on Network Pharmacology and Molecular Docking.</ArticleTitle><Pagination><StartPage>8942415</StartPage><MedlinePgn>8942415</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">8942415</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1155/2023/8942415</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Systemic lupus erythematosus (SLE) is characterized by poor regulation of the immune response leading to chronic inflammation and multiple organ dysfunction. Glucocorticoid (GC) is currently one of the main treatments. However, a high dose or prolonged use of GC may result in glucocorticoid-induced osteoporosis (GIOP). Jiedu Quyu Ziyin decoction (JP) is effective in treating SLE and previous clinical studies have proved that JP can prevent and treat SLE steroid osteoporosis (SLE-GIOP). We aim to examine JPs main mechanism on SLE-GIOP through network pharmacology and molecular docking.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">TCMSP and TCMID databases were used to screen potential active compounds and targets of JP. The SLE-GIOP targets are collected from GeneCards, OMIM, PharmGkb, TTD, and DrugBank databases. R software was used to obtain the cross-targets of JP and SLE-GIOP and to perform GO and KEGG enrichment analysis. Cytoscape software was used to make the Chinese Medicines-Active Ingredient-Intersection Targets network diagram. STRING database construct protein-protein interaction network and obtain the core targets. Auto Dock Tools and Pymol software were used for docking.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Fifty eight targets overlapped between JP and SLE-GIOP were suggested as potential targets of JP in the treatment of SLE-GIOP. Network topology analysis identified five core targets. GO enrichment analysis was obtained 1,968 items, and the top 10 biological process, closeness centrality, and molecular function were displayed. A total of 154 signaling pathways were obtained by KEGG enrichment analysis, and the top 30 signaling pathways were displayed. JP was well bound by MAPK1, TP53, and MYC according to the molecular docking results.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">We investigated the potential targets and signaling pathways of JP against SLE-GIOP in this study. It shows that JP is most likely to achieve the purpose of treating SLE-GIOP by promoting the proliferation and differentiation of osteoblasts. A solid theoretical foundation will be provided for the future study of clinical and experimental topics.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Jie Li et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jie</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0001-6453-2618</Identifier><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Run-Yu</ForeName><Initials>RY</Initials><Identifier Source="ORCID">0009-0004-1874-1701</Identifier><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Lin-Feng</ForeName><Initials>LF</Initials><Identifier Source="ORCID">0009-0003-0826-3534</Identifier><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Su-Hai</ForeName><Initials>SH</Initials><Identifier Source="ORCID">0000-0002-7746-1951</Identifier><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Rong-Yun</ForeName><Initials>RY</Initials><Identifier Source="ORCID">0000-0002-7201-3201</Identifier><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lan</LastName><ForeName>Ji-le</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0003-0717-0478</Identifier><AffiliationInfo><Affiliation>College of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Lin</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-8036-8408</Identifier><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Xing-Hong</ForeName><Initials>XH</Initials><Identifier Source="ORCID">0000-0001-7090-9445</Identifier><AffiliationInfo><Affiliation>School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Egypt</Country><MedlineTA>J Immunol Res</MedlineTA><NlmUniqueID>101627166</NlmUniqueID><ISSNLinking>2314-7156</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000091484" MajorTopicYN="N">Network Pharmacology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010024" MajorTopicYN="Y">Osteoporosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004365" MajorTopicYN="Y">Drugs, Chinese Herbal</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>7</Day><Hour>2</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37026113</ArticleId><ArticleId IdType="pmc">PMC10072964</ArticleId><ArticleId IdType="doi">10.1155/2023/8942415</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiriakidou M., Ching C. L. Systemic lupus erythematosus. Annals of Internal Medicine . 2020;172(11):ITC81&#x2013;ITC96. doi: 10.7326/AITC202006020.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/AITC202006020</ArticleId><ArticleId IdType="pubmed">32479157</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Irastorza G., Danza A., Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology . 2012;51(7):1145&#x2013;1153. doi: 10.1093/rheumatology/ker410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ker410</ArticleId><ArticleId IdType="pubmed">22271756</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchimont N., Canalis E. Management of glucocorticoid induced osteoporosis in premenopausal women with autoimmune disease. Autoimmunity Reviews . 2003;2(4):224&#x2013;228. doi: 10.1016/S1568-9972(03)00056-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1568-9972(03)00056-9</ArticleId><ArticleId IdType="pubmed">12848950</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y. S., Wen G. P., Wu G. L., Li X. M. Study on the prevention and treatment of systemic lupus erythematosus steroid osteoporosis by Jiedu Quyu Ziyin Decoction. Chinese Journal of Traditional Chinese Medicine . 2005;(11):28&#x2013;30+5.</Citation></Reference><Reference><Citation>Wen G. P., Fan Y. S., Tang X. P. Experimental study of Jiedu Quyu Ziyin decoction on preventing and treating corticosteroid osteoporosis in SLE. China Journal of Traditional Chinese Medicine and Pharmacy . 2007;7:430&#x2013;433.</Citation></Reference><Reference><Citation>Ru J., Li P., Wang J., et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. Journal of Cheminformatics . 2014;6 doi: 10.1186/1758-2946-6-13.13</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1758-2946-6-13</ArticleId><ArticleId IdType="pmc">PMC4001360</ArticleId><ArticleId IdType="pubmed">24735618</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L., Xie D., Yu Y., et al. TCMID 2.0: a comprehensive resource for TCM. Nucleic Acids Research . 2018;46(D1):D1117&#x2013;D1120. doi: 10.1093/nar/gkx1028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx1028</ArticleId><ArticleId IdType="pmc">PMC5753259</ArticleId><ArticleId IdType="pubmed">29106634</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J., Stevenson J. Drug-like index: a new approach to measure drug-like compounds and their diversity. Journal of Chemical Information and Computer Sciences . 2000;40(5):1177&#x2013;1187. doi: 10.1021/ci000026+.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ci000026+</ArticleId><ArticleId IdType="pubmed">11045811</ArticleId></ArticleIdList></Reference><Reference><Citation>The UniProt Consortium. UniProt: the universal protein knowledgebase. Nucleic Acids Research . 2018;46(5) doi: 10.1093/nar/gky092.2699</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky092</ArticleId><ArticleId IdType="pmc">PMC5861450</ArticleId><ArticleId IdType="pubmed">29425356</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang M., Yu S., Shao Q., et al. Comprehensive profiling of Lingzhihuang capsule by liquid chromatography coupled with mass spectrometry-based molecular networking and target prediction. Acupuncture and Herbal Medicine . 2022;2(1):58&#x2013;67. doi: 10.1097/HM9.0000000000000012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HM9.0000000000000012</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon P., Markiel A., Ozier O., et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Research . 2003;13:2498&#x2013;2504. doi: 10.1101/gr.1239303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.1239303</ArticleId><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook H. V., Doncheva N. T., Szklarczyk D., Von Mering C., Jensen L. J. Viruses.STRING: a virus-host protein&#x2013;protein interaction database. Viruses . 2018;10(10) doi: 10.3390/v10100519.519</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v10100519</ArticleId><ArticleId IdType="pmc">PMC6213343</ArticleId><ArticleId IdType="pubmed">30249048</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y., Li M., Wang J., Pan Y., Wu F.-X. CytoNCA: a cytoscape plugin for centrality analysis and evaluation of protein interaction networks. Biosystems . 2015;127:67&#x2013;72. doi: 10.1016/j.biosystems.2014.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biosystems.2014.11.005</ArticleId><ArticleId IdType="pubmed">25451770</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W., Fan Y. H., Tian C. Y., et al. Deciphering the molecular targets and mechanisms of HGWD in the treatment of rheumatoid arthritis via network pharmacology and molecular docking. Evidence-Based Complementary and Alternative Medicine . 2020;2020:13. doi: 10.1155/2020/7151634.7151634</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/7151634</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Liu Z., Li C., et al. Drug target prediction based on the herbs components: the study on the multitargets pharmacological mechanism of qishenkeli acting on the coronary heart disease. Evidence-Based Complementary and Alternative Medicine . 2012;2012:10. doi: 10.1155/2012/698531.698531</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/698531</ArticleId><ArticleId IdType="pmc">PMC3310183</ArticleId><ArticleId IdType="pubmed">22474514</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y., Liu W., Jin Y., et al. Integrated molecular docking with network pharmacology to reveal the molecular mechanism of simiao powder in the treatment of acute gouty arthritis. Evidence-Based Complementary and Alternative Medicine . 2021;2021:15. doi: 10.1155/2021/5570968.5570968</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/5570968</ArticleId><ArticleId IdType="pmc">PMC8100412</ArticleId><ArticleId IdType="pubmed">34007291</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen N. T., Nguyen T. H., Pham T. N. H., et al. Autodock vina adopts more accurate binding poses but autodock4 forms better binding affinity. Journal of Chemical Information and Modeling . 2020;60(1):204&#x2013;211. doi: 10.1021/acs.jcim.9b00778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jcim.9b00778</ArticleId><ArticleId IdType="pubmed">31887035</ArticleId></ArticleIdList></Reference><Reference><Citation>Chotiyarnwong P., McCloskey E. V. Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nature Reviews Endocrinology . 2020;16:437&#x2013;447. doi: 10.1038/s41574-020-0341-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41574-020-0341-0</ArticleId><ArticleId IdType="pubmed">32286516</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X., Fan Y., Wen C. Study on the characteristics of systemic lupus erythematosus syndrome, clinical therapeutic effect and mechanism of traditional chinese medicine. Journal of Zhejiang Chinese Medical University . 2019;(6):1108&#x2013;1113.</Citation></Reference><Reference><Citation>Boezio B., Audouze K., Ducrot P., Taboureau O. Network-based approaches in pharmacology. Molecular Informatics . 2017;36(10) doi: 10.1002/minf.201700048.1700048</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/minf.201700048</ArticleId><ArticleId IdType="pubmed">28692140</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong S. K., Chin K.-Y., Ima-Nirwana S. Quercetin as an agent for protecting the bone: a review of the current evidence. International Journal of Molecular Sciences . 2020;21(17) doi: 10.3390/ijms21176448.6448</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21176448</ArticleId><ArticleId IdType="pmc">PMC7503351</ArticleId><ArticleId IdType="pubmed">32899435</ArticleId></ArticleIdList></Reference><Reference><Citation>dos Santos M., Poletti P. T., Favero G., et al. Protective effects of quercetin treatment in a pristane-induced mouse model of lupus nephritis. Autoimmunity . 2018;51(2):69&#x2013;80. doi: 10.1080/08916934.2018.1442828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916934.2018.1442828</ArticleId><ArticleId IdType="pubmed">29480020</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., Li H., Zhang M., et al. Quercitrin ameliorates the development of systemic lupus erythematosus-like disease in a chronic graft-versus-host murine model. American Journal of Physiology-Renal Physiology . 2016;311(1):F217&#x2013;F226. doi: 10.1152/ajprenal.00249.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajprenal.00249.2015</ArticleId><ArticleId IdType="pubmed">26911849</ArticleId></ArticleIdList></Reference><Reference><Citation>Jing Z., Wang C., Yang Q., et al. Luteolin attenuates glucocorticoid-induced osteoporosis by regulating ERK/Lrp-5/GSK-3&#x3b2; signaling pathway in vivo and in vitro. Journal of Cellular Physiology . 2019;234(4):4472&#x2013;4490. doi: 10.1002/jcp.27252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.27252</ArticleId><ArticleId IdType="pubmed">30192012</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng L. Luteolin stimulates proliferation and inhibits late differentiation of primary rat calvarial osteoblast induced by high-dose dexamethasone via Sema3A/NRP1/Pleixin A1. Current Pharmaceutical Biotechnology . 2021;22(11):1538&#x2013;1545. doi: 10.2174/1389201021666201216150442.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389201021666201216150442</ArticleId><ArticleId IdType="pubmed">33327910</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong S. K., Chin K. Y., Ima-Nirwana S. The osteoprotective effects of kaempferol: the evidence from in vivo and in vitro studies. Drug Design, Development and Therapy . 2019;13:3497&#x2013;3514. doi: 10.2147/DDDT.S227738.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S227738</ArticleId><ArticleId IdType="pmc">PMC6789172</ArticleId><ArticleId IdType="pubmed">31631974</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin F., Luo X., Tsun A., Li Z., Li D., Li B. Kaempferol enhances the suppressive function of Treg cells by inhibiting FOXP3 phosphorylation. International Immunopharmacology . 2015;28(2):859&#x2013;865. doi: 10.1016/j.intimp.2015.03.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2015.03.044</ArticleId><ArticleId IdType="pubmed">25870037</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S.-F., Tang J.-J., Chen J., et al. Regulation of bone formation by baicalein via the mTORC1 pathway. Drug Design, Development and Therapy . 2015;9:5169&#x2013;5183. doi: 10.2147/DDDT.S81578.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S81578</ArticleId><ArticleId IdType="pmc">PMC4572734</ArticleId><ArticleId IdType="pubmed">26392752</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim M. H., Ryu S. Y., Bae M. A., Choi J.-S., Min Y. K., Kim S. H. Baicalein inhibits osteoclast differentiation and induces mature osteoclast apoptosis. Food and Chemical Toxicology . 2008;46(11):3375&#x2013;3382. doi: 10.1016/j.fct.2008.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fct.2008.08.016</ArticleId><ArticleId IdType="pubmed">18786594</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D., Shi G., Wang J., et al. Baicalein ameliorates pristane-induced lupus nephritis via activating Nrf2/HO-1 in myeloid-derived suppressor cells. Arthritis Research &amp; Therapy . 2019;21 doi: 10.1186/s13075-019-1876-0.105</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-019-1876-0</ArticleId><ArticleId IdType="pmc">PMC6482536</ArticleId><ArticleId IdType="pubmed">31023362</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin X., Yuan G., Li Z., et al. Ellagic acid protects ovariectomy-induced bone loss in mice by inhibiting osteoclast differentiation and bone resorption. Journal of Cellular Physiology . 2020;235(9):5951&#x2013;5961. doi: 10.1002/jcp.29520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.29520</ArticleId><ArticleId IdType="pubmed">32026468</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H., Chen F., Liu T., et al. Ellagic acid blocks RANKL&#x2013;RANK interaction and suppresses RANKL-induced osteoclastogenesis by inhibiting RANK signaling pathways. Chemico-Biological Interactions . 2020;331 doi: 10.1016/j.cbi.2020.109235.109235</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbi.2020.109235</ArticleId><ArticleId IdType="pubmed">32971123</ArticleId></ArticleIdList></Reference><Reference><Citation>Rantlha M., Sagar T., Kruger M. C., Coetzee M., Deepak V. Ellagic acid inhibits RANKL-induced osteoclast differentiation by suppressing the p38 MAP kinase pathway. Archives of Pharmacal Research . 2017;40:79&#x2013;87. doi: 10.1007/s12272-016-0790-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12272-016-0790-0</ArticleId><ArticleId IdType="pubmed">27384064</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng S., Dai G., Chen S., et al. Dexamethasone induces osteoblast apoptosis through ROS-PI3K/AKT/GSK3&#x3b2; signaling pathway. Biomedicine &amp; Pharmacotherapy . 2019;110:602&#x2013;608. doi: 10.1016/j.biopha.2018.11.103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2018.11.103</ArticleId><ArticleId IdType="pubmed">30537677</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H., Li X., Lin J., Lin M. Morroniside promotes the osteogenesis by activating PI3K/Akt/mTOR signaling. Bioscience, Biotechnology, and Biochemistry . 2021;85(2):332&#x2013;339. doi: 10.1093/bbb/zbaa010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bbb/zbaa010</ArticleId><ArticleId IdType="pubmed">33604633</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H., Jiao G., Dong M., et al. Orthosilicic acid accelerates bone formation in human osteoblast-like cells through the PI3K&#x2013;Akt&#x2013;mTOR pathway. Biological Trace Element Research . 2019;190:327&#x2013;335. doi: 10.1007/s12011-018-1574-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12011-018-1574-9</ArticleId><ArticleId IdType="pubmed">30421162</ArticleId></ArticleIdList></Reference><Reference><Citation>Be&#x15f;liu A. N., Pistol G., Marica C. M., et al. PI3K/Akt signaling in peripheral T lymphocytes from systemic lupus erythematosus patients. Roumanian Archives of Microbiology and Immunology . 2009;68(2):69&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">20361524</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong L.-J., Chen A.-J., Li F.-Z., Chen K.-J., Fang S. The HSP90 inhibitor, 17-AAG, influences the activation and proliferation of T lymphocytes via AKT/GSK3&#x3b2; signaling in MRL/lpr mice. Drug Design, Development and Therapy . 2020;14:4605&#x2013;4612. doi: 10.2147/DDDT.S269725.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S269725</ArticleId><ArticleId IdType="pmc">PMC7605613</ArticleId><ArticleId IdType="pubmed">33149557</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Xie L., Wang S., Lin J., Liang J., Xu J. Azithromycin promotes alternatively activated macrophage phenotype in systematic lupus erythematosus via PI3K/Akt signaling pathway. Cell Death &amp; Disease . 2018;9 doi: 10.1038/s41419-018-1097-5.1080</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-018-1097-5</ArticleId><ArticleId IdType="pmc">PMC6197274</ArticleId><ArticleId IdType="pubmed">30348950</ArticleId></ArticleIdList></Reference><Reference><Citation>MacFarlane E. G., Haupt J., Dietz H. C., Shore E. M. TGF-&#x3b2; family signaling in connective tissue and skeletal diseases. Cold Spring Harbor Perspectives in Biology . 2017;9(11) doi: 10.1101/cshperspect.a022269.a022269</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a022269</ArticleId><ArticleId IdType="pmc">PMC5666637</ArticleId><ArticleId IdType="pubmed">28246187</ArticleId></ArticleIdList></Reference><Reference><Citation>Aslani S., Abhari A., Sakhinia E., Sanajou D., Rajabi H., Rahimzadeh S. Interplay between microRNAs and Wnt, transforming growth factor-&#x3b2;, and bone morphogenic protein signaling pathways promote osteoblastic differentiation of mesenchymal stem cells. Journal of Cellular Physiology . 2019;234(6):8082&#x2013;8093. doi: 10.1002/jcp.27582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.27582</ArticleId><ArticleId IdType="pubmed">30548580</ArticleId></ArticleIdList></Reference><Reference><Citation>Tashjian A. H., Jr, Voelkel E. F., Lazzaro M., et al. Alpha and beta human transforming growth factors stimulate prostaglandin production and bone resorption in cultured mouse calvaria. Proceedings of the National Academy of Sciences . 1985;82(13):4535&#x2013;4538. doi: 10.1073/pnas.82.13.4535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.82.13.4535</ArticleId><ArticleId IdType="pmc">PMC391137</ArticleId><ArticleId IdType="pubmed">3859875</ArticleId></ArticleIdList></Reference><Reference><Citation>Dieudonn&#xe9; S. C., Foo P., Van Zoelen E. J., Burger E. H. Inhibiting and stimulating effects of TGF-&#x3b2;1 on osteoclastic bone resorption in fetal mouse bone organ cultures. Journal of Bone and Mineral Research . 1991;6(5):479&#x2013;487. doi: 10.1002/jbmr.5650060509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jbmr.5650060509</ArticleId><ArticleId IdType="pubmed">2068954</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneda T., Nojima T., Nakagawa M., et al. Endogenous production of TGF-&#x3b2; is essential for osteoclastogenesis induced by a combination of receptor activator of NF-&#x3ba;B ligand and macrophage-colony-stimulating factor. The Journal of Immunology . 2000;165(8):4254&#x2013;4263. doi: 10.4049/jimmunol.165.8.4254.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.165.8.4254</ArticleId><ArticleId IdType="pubmed">11035059</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn J. M. W., Itoh K., Udagawa N., et al. Transforming growth factor &#x3b2; affects osteoclast differentiation via direct and indirect actions. Journal of Bone and Mineral Research . 2001;16(10):1787&#x2013;1794. doi: 10.1359/jbmr.2001.16.10.1787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1359/jbmr.2001.16.10.1787</ArticleId><ArticleId IdType="pubmed">11585342</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammad K. S., Chen C. G., Balooch G., et al. Pharmacologic inhibition of the TGF-&#x3b2; type I receptor kinase has anabolic and anti-catabolic effects on bone. PLOS ONE . 2009;4(4) doi: 10.1371/journal.pone.0005275.e5275</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0005275</ArticleId><ArticleId IdType="pmc">PMC2666804</ArticleId><ArticleId IdType="pubmed">19357790</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang S. Y., Alliston T. Regulation of postnatal bone homeostasis by TGF&#x3b2;. BoneKEy Reports . 2013;2 doi: 10.1038/bonekey.2012.255.255</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bonekey.2012.255</ArticleId><ArticleId IdType="pmc">PMC3722719</ArticleId><ArticleId IdType="pubmed">24404376</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohut E., Hajdu M., Gergely P., et al. Expression of TGF&#x3b2;1 and its signaling components by peripheral lymphocytes in systemic lupus erythematosus. Pathology &amp; Oncology Research . 2009;15:251&#x2013;256. doi: 10.1007/s12253-008-9119-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12253-008-9119-8</ArticleId><ArticleId IdType="pubmed">19020994</ArticleId></ArticleIdList></Reference><Reference><Citation>Onetti Muda A., Feriozzi S., Rahimi S., Faraggiana T. Expression of TGF-beta receptors type I and II in human glomerulonephritis. Nephrology Dialysis Transplantation . 1998;13(2):279&#x2013;284. doi: 10.1093/oxfordjournals.ndt.a027819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.ndt.a027819</ArticleId><ArticleId IdType="pubmed">9509435</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>